Janux is developing unique T cell immunotherapies designed to generate tumor-specific immune responses to kill tumors without impacting healthy tissue.

Janux is creating novel immunotherapies with its proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms.

Check out the drug pipeline for Janux Therapeutics, a clinical-stage biopharmaceutical company developing a broad pipeline of novel T cell immunotherapies. Janux Selects Doses for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Trial for JANX007 in mCRPC.

Janux is a clinical-stage company developing unique immunotherapies that have the potential to generate tumor-specific immune responses to attack and kill tumors without destroying a patient’s healthy tissue.

Dec 4, 2024 · At Janux, we are developing unique immunotherapies that have the potential to generate tumor-specific immune responses to attack and kill tumors without destroying a patient’s healthy tissue.

Feb 26, 2024 · Janux is currently developing a broad pipeline of TRACTr and TRACIr therapeutics directed at several targets to treat solid tumors. Janux has two TRACTr therapeutic candidates in clinical trials, the first targeting PSMA is in development for prostate cancer, and the second targeting EGFR is being developed for colorectal, lung, head and neck ...

JANX007 is Janux’s lead novel Tumor Activated T Cell Engager (TRACTr). JANX007 is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of tumors and is in the clinic for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

Check out job opportunities at Janux Therapeutics, a clinical-stage biopharmaceutical company developing a broad pipeline of novel T cell immunotherapies.

Janux is developing tumor-activated immunotherapies precision-engineered to direct T cells to kill tumors without impacting a patient's healthy tissue. Janux Selects Doses for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Trial for JANX007 in mCRPC.

Learn about clinical trials at Janux Therapeutics, a clinical-stage biopharmaceutical company developing a broad pipeline of novel T cell immunotherapies.